Form 4: Amgen VP Acquires Shares Through Dividend Reinvestment Plan

Matthew C. Busch, VP of Finance & CAO at Amgen, acquired 497 shares of common stock through a dividend reinvestment plan.

Summary

• On March 3, 2025, Matthew C. Busch, VP of Finance & CAO at Amgen, acquired 497 shares of Amgen common stock.
• The acquisition was made through a dividend reinvestment plan at a price of $0 per share.
• Following the transaction, Busch directly owns 5,277 shares of Amgen common stock.
• The shares include 100 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan.
• DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a routine transaction related to dividend reinvestment.

Positives

• The acquisition of shares by a company executive can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This is a routine Form 4 filing, reflecting an executive's acquisition of company stock through a pre-existing dividend reinvestment plan. It's a common practice among publicly traded companies to offer such plans to employees and executives.

Stakeholder Impact

• The transaction has a minimal impact on stakeholders as it's a routine acquisition of shares by an executive.

Key Dates